<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s4{border-left: none;background-color:#ffffff;}.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s8{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#1155cc;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{border-left: none;border-right: none;background-color:#ffffff;}.ritz .waffle .s1{border-right: none;background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="189632280C0" style="width:624px;" class="column-headers-background">A</th><th id="189632280C1" style="width:100px;" class="column-headers-background">B</th></tr></thead><tbody><tr style="height: 20px"><th id="189632280R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Overactive Bladder aka Urge Incontinence</td><td></td></tr><tr style="height: 20px"><th id="189632280R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="189632280R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1222px;left:-1px">Summary stepwise management<br><span style="font-weight:normal;">Lifestyle measures: fluid / diet (avoidance of irritants / artificial things) / constipation / smoking / stress / exercise - signpost to bladder health UK <br>Bladder retraining: timed voids with pausing for 5-15 minutes when urge present - signpost to leaflets<br>PFE: help strengthen the muscles which hold onto urine - signpost to website<br>Meds: antimuscarinics / mirabegron / consider vaginal oestrogen and desmopressin, discuss chance of success, side effects, avoid oxybutynin if frail, transdermal if oral not tolerated, review in 4 weeks<br>If above fails, consider urodynamics<br>Botox / Neuromodulation /  Augmentation cystoplasty</span></div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="189632280R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s0" dir="ltr">Check for any of the following co-morbidities:</td><td></td></tr><tr style="height: 20px"><th id="189632280R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s3" dir="ltr">cognitive impairment / dementia</td><td></td></tr><tr style="height: 20px"><th id="189632280R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s0" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:722px;left:-1px">If any of the following medications are already being taken, they may lead to excessive anticholinergic load:</div></td><td class="s4"></td></tr><tr style="height: 20px"><th id="189632280R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s3" dir="ltr">antihistamines, tricyclic antidepressants, drugs for asthma and COPD, cold preparations, hyoscine</td><td></td></tr><tr style="height: 20px"><th id="189632280R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s5" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s5" dir="ltr">Before starting treatment with a medicine for overactive bladder, explain to the patient: </td><td></td></tr><tr style="height: 20px"><th id="189632280R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s3" dir="ltr">Approx 50-65% of patients find medications at least partially beneficial</td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">1. the likelihood of the medicine being successful </div></td></tr><tr style="height: 20px"><th id="189632280R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td></td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">2. the common adverse effects associated with the medicine </div></td></tr><tr style="height: 20px"><th id="189632280R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td></td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">3. that some adverse effects of anticholinergic medicines, such as dry mouth and constipation, may indicate that the medicine is starting to have an effect </div></td></tr><tr style="height: 20px"><th id="189632280R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td></td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">4. that she may not see substantial benefits until she has been taking the medicine for at least 2 weeks and that her symptoms may continue to improve over time </div></td></tr><tr style="height: 20px"><th id="189632280R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td></td><td class="s6 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">5. that the long-term effects of anticholinergic medicines for overactive bladder on cognitive function are uncertain</div></td></tr><tr style="height: 20px"><th id="189632280R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td></td><td></td></tr><tr style="height: 20px"><th id="189632280R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s1 softmerge" dir="ltr"><div class="softmerge-inner" style="width:722px;left:-1px">When offering anticholinergic medicines to treat overactive bladder, take account of the woman&#39;s:</div></td><td class="s4"></td></tr><tr style="height: 20px"><th id="189632280R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s3" dir="ltr">coexisting conditions (such as poor bladder emptying, cognitive impairment or dementia)</td><td></td></tr><tr style="height: 20px"><th id="189632280R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s3" dir="ltr">current use of other medicines that affect total anticholinergic load</td><td></td></tr><tr style="height: 20px"><th id="189632280R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s3" dir="ltr">risk of adverse effects, including cognitive impairment.</td><td></td></tr><tr style="height: 20px"><th id="189632280R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s3" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1322px;left:-1px">For women who have a diagnosis of dementia and for whom anticholinergic medicines are an option, follow the recommendations on medicines that may cause cognitive impairment in the NICE guideline on dementia.</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s3" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s0" dir="ltr">Choosing medicine</td><td></td></tr><tr style="height: 20px"><th id="189632280R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:722px;left:-1px">Do not offer women flavoxate, propantheline or imipramine to treat urinary incontinence or overactive bladder. [2013]</div></td><td class="s4"></td></tr><tr style="height: 20px"><th id="189632280R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:922px;left:-1px">Do not offer oxybutynin (immediate release) to older women who may be at higher risk of a sudden deterioration in their physical or mental health.</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:922px;left:-1px">Offer the anticholinergic medicine with the lowest acquisition cost to treat overactive bladder or mixed urinary incontinence in women. [2019]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:922px;left:-1px">If the first medicine for overactive bladder or mixed urinary incontinence is not effective or well-tolerated, offer another medicine with a low acquisition cost</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s3" dir="ltr">Offer a transdermal overactive bladder treatment to women unable to tolerate oral medicines. [2013]</td><td></td></tr><tr style="height: 20px"><th id="189632280R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:922px;left:-1px">For guidance on mirabegron, see the NICE technology appraisal guidance on mirabegron for treating symptoms of overactive bladder. [2013]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1622px;left:-1px">The use of desmopressin may be considered specifically to reduce nocturia in women with urinary incontinence or overactive bladder who find it a troublesome symptom. Use particular caution in women withÂ [...]Â and avoid in those overÂ [...]Â years withÂ [...]Â orÂ [...]. [2013]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s3" dir="ltr">Do not use duloxetine as a first-line treatment for women with predominant stress urinary incontinence.</td><td></td></tr><tr style="height: 20px"><th id="189632280R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1522px;left:-1px">Do not routinely offer duloxetine as a second-line treatment for women with stress urinary incontinence, although it may be offered as second-line therapy if women prefer pharmacological to surgical treatment or are not suitable for surgical treatment.</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s3" dir="ltr">If duloxetine is prescribed, counsel women about its adverse effects. [2006]</td><td></td></tr><tr style="height: 20px"><th id="189632280R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s3" dir="ltr">Do not offer systemic hormone replacement therapy to treat urinary incontinence. [2006]</td><td></td></tr><tr style="height: 20px"><th id="189632280R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:822px;left:-1px">Offer intravaginal oestrogens to treat overactive bladder symptoms in postmenopausal women with vaginal atrophy. [2006]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td class="s3" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s0" dir="ltr">Reviewing medicine</td><td></td></tr><tr style="height: 20px"><th id="189632280R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:3140px;left:-1px">Offer a face-to-face or telephone review 4 weeks after starting a new medicine for overactive bladder. Ask the woman if she is satisfied with the treatment}} and if improvement is optimal, continue treatment and if there is no or suboptimal improvement, or intolerable adverse effects, change the dose or try an alternative medicine for overactive bladder (see the recommendations for when the first medicine is not effective and offering a transdermal patch in the section on choosing medicines), and review again 4 weeks later. [2013]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R40" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">41</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:722px;left:-1px">Offer a review before 4 weeks if the adverse events of a medicine for overactive bladder are intolerable. [2013]</div></td><td class="s4"></td></tr><tr style="height: 20px"><th id="189632280R41" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">42</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1022px;left:-1px">Refer women who have tried taking medicine for overactive bladder, but for whom it has not been successful or tolerated, to secondary care to consider further treatment.</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R42" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">43</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1022px;left:-1px">Offer a further face-to-face or telephone review if a medicine for overactive bladder or urinary incontinence stops working after an initial successful 4â€‘week review. [2013]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R43" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">44</div></th><td class="s7 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1222px;left:-1px">Offer a review in primary care to women who remain on long-term medicine for overactive bladder or urinary incontinence every 12 months, or every 6 months if they are aged over 75. [2013, amended 2019]</div></td><td class="s2"></td></tr><tr style="height: 20px"><th id="189632280R44" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">45</div></th><td class="s3" dir="ltr"></td><td></td></tr><tr style="height: 20px"><th id="189632280R45" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">46</div></th><td class="s0" dir="ltr">References:</td><td></td></tr><tr style="height: 20px"><th id="189632280R46" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">47</div></th><td class="s8" dir="ltr"><a target="_blank" href="https://bladderhealthuk.org/">Lifestyle Measures</a></td><td></td></tr><tr style="height: 20px"><th id="189632280R47" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">48</div></th><td class="s8" dir="ltr"><a target="_blank" href="https://www.ouh.nhs.uk/patient-guide/leaflets/files/65610Poveractivebladder.pdf">Bladder Retraining</a></td><td></td></tr><tr style="height: 20px"><th id="189632280R48" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">49</div></th><td class="s8" dir="ltr"><a target="_blank" href="https://www.nhs.uk/planners/pregnancycareplanner/documents/bandbf_pelvic_floor_women.pdf">Pelvic Floor Exercises</a></td><td></td></tr></tbody></table></div>